Korea Investment CORP Invests $9.64 Million in United Therapeutics Corporation $UTHR

Key Points

• Korea Investment CORP acquired 17,800 shares of United Therapeutics in the second quarter, worth approximately $9.645 million. Institutional investors and hedge funds collectively own 94.08% of UTHR.
• Analysts maintain a generally positive outlook, with 11 Buy ratings and two Hold ratings, producing a “Moderate Buy” consensus and an average price target of $646.00.
• United Therapeutics exceeded quarterly EPS expectations, reporting $7.27 versus the $6.86 consensus, although revenue of $783.3 million missed estimates and declined 1.9% year over year. Insiders sold approximately $233.9 million of stock during the quarter.

Korea Investment CORP acquired a new position in shares of United Therapeutics Corporation (NASDAQ:UTHR - Free Report) during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 17,800 shares of the biotechnology company's stock, valued at approximately $9,645,000.

Several other large investors have also modified their holdings of UTHR. Torren Management LLC purchased a new position in United Therapeutics during the 4th quarter worth approximately $26,000. Activest Wealth Management boosted its holdings in shares of United Therapeutics by 1,400.0% in the fourth quarter. Activest Wealth Management now owns 60 shares of the biotechnology company's stock valued at $29,000 after acquiring an additional 56 shares during the period. WealthCollab LLC boosted its holdings in shares of United Therapeutics by 55.9% in the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company's stock valued at $30,000 after acquiring an additional 38 shares during the period. Rakuten Securities Inc. grew its position in shares of United Therapeutics by 76.7% during the second quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company's stock worth $30,000 after acquiring an additional 46 shares during the last quarter. Finally, Entrust Financial LLC acquired a new position in shares of United Therapeutics in the 4th quarter valued at $31,000. Institutional investors and hedge funds own 94.08% of the company's stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on UTHR shares. Royal Bank Of Canada dropped their price target on shares of United Therapeutics from $704.00 to $677.00 and set an "outperform" rating on the stock in a research note on Thursday, August 6th. Bank of America lowered their price objective on United Therapeutics from $620.00 to $613.00 and set a "neutral" rating on the stock in a report on Friday, July 10th. TD Cowen reissued a "buy" rating on shares of United Therapeutics in a research note on Thursday, May 21st. Weiss Ratings upgraded United Therapeutics from a "buy (b-)" rating to a "buy (b)" rating in a research report on Thursday, August 13th. Finally, Morgan Stanley set a $515.00 target price on United Therapeutics in a report on Thursday, August 6th. Eleven investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company's stock. According to MarketBeat, United Therapeutics currently has an average rating of "Moderate Buy" and an average target price of $646.00.

United Therapeutics Stock Down 0.0%

Shares of NASDAQ UTHR opened at $512.88 on Tuesday. United Therapeutics Corporation has a fifty-two week low of $302.19 and a fifty-two week high of $609.35. The business has a 50 day moving average price of $532.35 and a two-hundred day moving average price of $538.04. The firm has a market cap of $22.00 billion, a PE ratio of 18.35, a price-to-earnings-growth ratio of 1.74 and a beta of 0.59.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last released its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $7.27 EPS for the quarter, topping analysts' consensus estimates of $6.86 by $0.41. The firm had revenue of $783.30 million during the quarter, compared to the consensus estimate of $804.65 million. United Therapeutics had a net margin of 41.56% and a return on equity of 20.18%. The firm's revenue was down 1.9% on a year-over-year basis. During the same quarter in the previous year, the company posted $6.41 earnings per share. On average, analysts anticipate that United Therapeutics Corporation will post 26.33 earnings per share for the current year.

Insider Buying and Selling at United Therapeutics

In other United Therapeutics news, CFO James Edgemond sold 10,000 shares of the company's stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $546.28, for a total value of $5,462,800.00. Following the transaction, the chief financial officer owned 18,876 shares of the company's stock, valued at approximately $10,311,581.28. This represents a 34.63% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Martine A. Rothblatt sold 9,500 shares of the firm's stock in a transaction that occurred on Wednesday, June 3rd. The stock was sold at an average price of $547.61, for a total transaction of $5,202,295.00. Following the completion of the transaction, the chief executive officer directly owned 40,513 shares of the company's stock, valued at $22,185,323.93. This represents a 19.00% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 434,075 shares of company stock worth $233,942,595. 8.60% of the stock is owned by insiders.

United Therapeutics Profile

United Therapeutics Corporation NASDAQ: UTHR is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company's primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.

Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Corporation (NASDAQ:UTHR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source